Aldeyra Therapeutics
ALDX
66 hedge funds and large institutions have $96.4M invested in Aldeyra Therapeutics in 2018 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 21 increasing their positions, 5 reducing their positions, and 5 closing their positions.
1,300% more call options, than puts
Call options by funds: $42K | Put options by funds: $3K
420% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 5
320% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 5
47% more funds holding
Funds holding: 45 → 66 (+21)
25% more capital invested
Capital invested by funds: $77.1M → $96.4M (+$19.3M)
6.53% more ownership
Funds ownership: 53.79% → 60.33% (+6.5%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.91M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.68M |
| 3 |
KC
Kepos Capital
New York
|
+$1.51M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$1.34M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.29M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$331K |
| 3 |
Millennium Management
New York
|
-$225K |
| 4 |
ECM
Element Capital Management
New York
|
-$123K |
| 5 |
Goldman Sachs
New York
|
-$117K |
ALDX Hedge Fund Activity: Q2 2018 in Review
66 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2018, worth a combined $96.4M — up 25% from $77.1M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ALDX positions and 5 closed out — a net gain of 21 holders — while 21 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $5.91M. The largest seller was Sphera Funds Management, cutting an estimated $1.29M.
- 66 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2018, up from 45 in Q1 2018.
- Funds reported $96.4M of Aldeyra Therapeutics stock for Q2 2018, up 25% quarter-over-quarter.
- 26 funds opened new Aldeyra Therapeutics positions in Q2 2018 and 5 closed out, a net change of +21 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2018 was BlackRock, an estimated $5.91M added.
- The largest Aldeyra Therapeutics seller in Q2 2018 was Sphera Funds Management, an estimated $1.29M sold.
Based on aggregated 13F filings for Q2 2018.